Chromocell Therapeutics Corp.
CHRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.9M
Close$
$-0.30
122.2% downside
Current Fair Value
122.2% downsideOvervalued by 122.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.90 Million |
|---|---|
| Enterprise Value | $26.09 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-23.04 |
| Beta | 3.29 |
| Outstanding Shares | 18,804,980 |
Return
| Return on Equity | -111.41% |
|---|---|
| Return on Assets | -33.22% |
| Return on Invested Capital | -33.75% |
Valuation & Multiples
| P/E Ratio | -0.59 |
|---|---|
| PEG | -0.06 |
| Price to Sales | - |
| Price to Book Ratio | 0.68 |
| Enterprise Value to Revenue | 1.55 |
| Enterprise Value to EBIT | -0.74 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.35 |
| Debt to Equity | 0.9 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data